

> THROMBOCYTOPENIA (PLT COUNT <150,000/µL)


# PLATELET DISORDERS

THROMBOCYTOPENIA (PLT COUNT <150,000/µL)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Thrombocytopenia and Risk of Bleeding</b></p></td></tr><tr><td><p><b>Platelet Count</b> (cells/µL)</p></td><td><p><b>Risk</b></p></td></tr><tr><td><p>50,000–100,000</p></td><td><p>Risk with major trauma; can proceed with general surgery</p></td></tr><tr><td><p>20,000–50,000</p></td><td><p>Risk with minor trauma or surgery</p></td></tr><tr><td><p>&lt;20,000</p></td><td><p>Risk of <i>spontaneous</i> bleeding (less so with ITP)</p></td></tr><tr><td><p>&lt;10,000</p></td><td><p>Risk of severe, life-threatening bleeding</p></td></tr></tbody></table>

原因

• ↓ **production**

**Hypocellular bone marrow:** aplastic anemia (qv), rarely MDS, drugs (eg, thiazides, antibiotics, chemotherapy), alcohol, cirrhosis

**Hypercellular bone marrow:** MDS, leukemia, severe megaloblastic anemia

**Marrow replacement:** myelofibrosis, hematologic and solid malignancies, granulomas

• ↑ **destruction**

### Immune-mediated (distinguish primary from secondary; _Blood_ 2009;113:2386) Primary (idiopathic): immune thrombocytopenic purpura (**ITP**, see below)

Secondary: infxn (**HIV**, **HCV**, HSV), collagen vascular diseases (**SLE**), APS, lymphoproliferative (**CLL**, lymphoma), drugs (_many_, including **heparin**, abciximab, quinidine, sulfonamides, vancomycin), alloimmune (posttransfusion)

### Non–immune-mediated: MAHA (DIC, HUS, TTP), ticlopidine/clopidogrel, vasculitis, preeclampsia/HELLP, cardiopulm bypass, CVVH, IABP, cavernous hemangioma, viral

• **Abnormal distribution or pooling:** splenic sequestration, dilutional, hypothermia

• **Unknown:** ehrlichiosis/anaplasmosis, babesiosis, RMSF

Diagnostic evaluation

• H&P: meds, infxns, underlying conditions, splenomegaly, lymph nodes, **bleeding hx**

• **CBC with differential:** isolated thrombocytopenia _vs._ multilineage involvement

• **Peripheral smear** (排除 pseudothrombocytopenia due to platelet clumping)

↑ destruction → look for large plts, **schistocytes** (see “Peripheral Smear” inserts)

↓ production → rarely limited to platelets → look for **blasts**, hypersegmented PMNs, leukoerythroblastic Δs; can see inclusion bodies (anaplasma), parasites (_Babesia_)

### Figure 5-5 Approach to thrombocytopenia

![](/Users/mac/Library/Mobile Documents/iCloud~md~obsidian/Documents/Obsidian/05血腫/images/00085.jpeg)

• Additional laboratory evaluations as indicated (eg, viral titers, flow cytometry, ANA, APLA)

if anemia: ✔ reticulocyte count, LDH, haptoglobin, bilirubin to detect hemolysis

if hemolytic anemia: ✔ PT, PTT, fibrinogen, D-dimer, Coombs, ANA

BM bx for unexplained thrombocytopenia, esp. if associated with splenomegaly

Primary immune thrombocytopenic purpura (ITP) (_Blood_ 2010;115:168)

• Isolated thrombocytopenia due to immune plt _destruction_ (auto-Ab to plts) & ↓ _production_ (auto-Ab to megakaryocytes) withoutut precipitant

• _Diagnosis of exclusion (排除 2_**°** _ITP);_ no robust 臨床or lab parameters, but typically:

CBC: isolated ↓ plt (<100,000/µL); 10% have ITP + AIHA = Evans syndrome

Peripheral smear: large platelets (not specific), 排除 pseudothrombocytopenia

BM bx: ↑ megakaryocytes, 正常 cellularity. Consider if other CBC or smear 異常 or diagnostic uncertainty (_Blood_ 2011;117:4910).

✔ HBSAg & anti-HBc prior to rituximab (and before IVIg, which could alter results)

臨床表現: insidious onset of mucocutaneous bleeding; ♀:♂ = 3:1

• 治療: rarely indicated if plt >50,000/µL unless bleeding, trauma/surgery, anticoag.

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><a id="page_5-8"></a><p><b>治療 of Primary ITP in Adults</b></p></td></tr><tr><td><p><b>Approach</b></p></td><td><p><b>治療</b></p></td><td><p><b>Notes</b></p></td></tr><tr><td rowspan="3"><p><b>First-line or upfront therapy</b></p></td><td><p><b>Steroids:</b> prednisone 0.5–2 mg/kg/d PO tapered ~4 wk, or dexamethasone 40 mg PO × 4 d</p></td><td><p>↓ Mφ FcR &amp; ↓ anti-plt Ab</p><p>70–90% have initial response</p><p>~20% sustained remission</p></td></tr><tr><td><p><b>IVIg</b> (1 g/kg/d IV × 2–3 d)</p><p><i>Consider if need rapid</i> ↑ <i>in plt in 24</i>–<i>48 hrs; lasts 2</i>–<i>6 wks</i></p></td><td><p>Blocks Mφ FcR, ↓ anti-plt Ab</p><p>Interferes with Mφ uptake Ab-coated plts; 80% have initial response</p></td></tr><tr><td><p>Anti-Rh(D) Ig: alternative to IVIg if RBC Rh(D) ⊕; 50–75 mcg/kg/d</p></td><td><p>Ab-coated RBCs overwhelm Mφ FcR</p><p>Avoid if h/o hemolysis; <i>not often used</i></p></td></tr><tr><td rowspan="5"><p><b>Second-line or maint. therapy</b></p></td><td><p><b>Romiplostim</b> or <b>eltrombopag</b></p></td><td><p>TPO-R agonists → ↑ plt prod</p></td></tr><tr><td><p><b>Rituximab</b> (anti-CD20) ± dex</p></td><td><p>anti–B-cell Ab</p></td></tr><tr><td><p><b>Splenectomy</b> <i>(less common)</i></p></td><td><p>~65% long-term remission</p></td></tr><tr><td><p>AZA, CYC, MMF</p></td><td><p>Immunosuppressants</p></td></tr><tr><td><p>Danazol: 600 mg/d</p></td><td><p>Androgen (hirsutism) ↓ plt clearance</p></td></tr><tr><td rowspan="2"><p><b>Chronic/ refractory</b></p></td><td><p><b>Romiplostim</b> or <b>eltrombopag</b></p></td><td><p>Allows splenectomy to be deferred</p></td></tr><tr><td><p><b>Fostamatinib:</b> 75–150 mg BID</p></td><td><p>Spleen tyrosine kinase (SYK) inhibitor</p></td></tr><tr><td rowspan="4"><p><b>Bleeding</b></p></td><td><p>Aminocaproic acid</p></td><td><p>Inhibits plasmin activation</p></td></tr><tr><td><p>Methylprednisolone 1g/d IV × 3 d</p></td><td><p>See above</p></td></tr><tr><td><p>IVIg</p></td><td><p>See above</p></td></tr><tr><td><p>Platelet transfusion</p></td><td><p>Given with IVIg or anti-Rh(D)</p></td></tr></tbody></table>

(_Blood_ 2017;129:2829 & 130:3624; _Lancet Haem_ 2016;3:e489; _Eur J Haem_ 2018;100:304; _Immunother_ 2018;10:9)

### Secondary immune thrombocytopenic purpura (2° ITP)

• Diagnosis: viral serologies (HIV, HCV, HBV, EBV), _H. pylori_ Ab, ANA, pregnancy test, APLA, TSH, parvovirus, & CMV PCR. _Anti-plt Ab tests not useful._

• Treat underlying etiology

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Heparin-Induced Thrombocytopenias</b> <span>(</span><span><i>Chest</i></span> <span>20</span><span>1</span><span>2;</span><span>1</span><span>4</span><span>1</span><span>:e495S;</span> <span><i>NE</i></span><span><i>JM</i></span> <span>20</span><span>1</span><span>5;373:252)</span></p></td></tr><tr><td><p><b>Feature</b></p></td><td><p><b>Type I</b> (not clin. signif)</p></td><td><p><b>Type II</b> (clinically significant HIT)</p></td></tr><tr><td><p><b>Mechanism</b></p></td><td><p>Direct effect of heparin (non-immune)</p></td><td><p>Immune (Ab)-mediated</p><p>IgG against plt factor 4—heparin complex</p></td></tr><tr><td><p><b>Incidence</b></p></td><td><p>10–20%</p></td><td><p>1–3% with UFH, 0–0.8% LMWH</p></td></tr><tr><td><p><b>Onset</b></p></td><td><p>After 1–4 d of heparin therapy</p></td><td><p>After 4–10 d; but can occur in &lt;24 h if prior exposure within 100 d (persistent Ab). Postop highest risk. Can occur after heparin d/c.</p></td></tr><tr><td><p><b>Platelet nadir</b></p></td><td><p>&gt;100,000/µL</p></td><td><p>~60,000/µL, ↓ &gt;50%</p></td></tr><tr><td><p><b>Sequelae</b></p></td><td><p>None</p></td><td><p>Thrombotic events <b>(HITT)</b> in 30–50%</p><p>Rare hemorrhagic complications</p></td></tr><tr><td><p><b>Management</b></p></td><td><p>Can continue heparin and observe</p></td><td><p><b>Discontinue heparin</b></p><p>Alternative anticoagulation</p></td></tr></tbody></table>

• 病生理 (type II): Ab binds heparin-PF4 → immune complex binds to plt → **plt activation**, further PF4 release → plt aggregates removed from circulation → **thrombocytopenia;** procoagulants released by plts and tissue factor released by endothelial cells damaged by HIT Abs → **prothrombotic state**

• Diagnosis _(need clinical_ + _pathologic)_

### Clinical:** plt <100k _or_ ↓ 50% from baseline; or venous** (DVT/PE) or **arterial** (limb ischemia, CVA, MI) thrombosis (4:1 ratio); skin necrosis; ? ↑ heparin resistance

**Pathologic:** ⊕ HIT Ab using PF4-heparin ELISA (≥90% Se, IgG-specific ELISA Sp 94%), may confirm with functional plt aggregation (serotonin-release) assay (>95% Se/Sp)

臨床context important: HIT Ab (esp. IgM ELISA) may be ⊕ in 10–20% of 病人 on UFH/LMWH (_Am J Hem_ 1996;52:90), up to 50% of cardiac bypass 病人 (_Circ_ 1997;95:1242)

Pretest prob with “4 T’s” criteria (_Blood_ 2012;120:4160): ≤3 points → 99% NPV, investigate other causes; 4–5 points 22% PPV & 6–8 points 64% PPV, ✔ lab test & replace UFH

![](https://i.imgur.com/H47THP7.jpg)

• 治療 of HIT (type II) (_Chest_ 2012;141:e495S; _Blood_ 2012;119:2209; _NEJM_ 2013;368:737)

### Discontinue heparin _(incl. flushes, LMWH Ppx, heparin lines)._ Avoid plts (anecdotal link with thrombosis); if given warfarin, give vit K to reverse, prevent warfarin skin necrosis.

### Nonheparin anticoag (argatroban, bivalirudin; _NEJM_ 2013;368:737) _regardless of thrombosis;_ start warfarin when plt >150k, overlap ≥5 d (✔ chromogenic Xa to titrate)

⊕ thrombosis (HITT): anticoagulate for ≥3–6 mo

⊖ thrombosis (HIT): screen for DVT; unclear duration of subsequent anticoag (until plt count recovers, often ~2–3 mo if no clot); _25–50% thrombosis rate within 30 d_

• H/o HIT: if PF4 Ab ⊖ or SRA ⊖ (typically >100 d after dx) → may consider re-exposure to UFH (eg, for surgery); HIT recurrence low but can be seen (_Blood_ 2014;123:2485)

Thrombotic microangiopathies (_TMA; NEJM_ 2014;371:654; _Lancet_ 2017;390:681)

• Endothelial injury → plt aggreg. & microvasc. thrombosis → ↓ plt & RBC hemolysis (MAHA)

• **Thrombotic thrombocytopenic purpura (TTP)**

Pathophys: ↓↓ ADAMTS13 protease activity (hereditary or autoAb) → persistence of large vWF multimers on endothelial surface → adhesion & aggregation of plts → thrombosis

Clinical: **pentad** (all 5 in only ~5%) = ↓ plts + MAHA (100%) ± Δ MS (65%) ± renal failure (50%, late feature) ± fever (25%)

• **Hemolytic-uremic syndrome (HUS)**

Pathophys: (1) Shiga toxin damages renal endothelial cells → intrarenal thrombi; _or_ (2) complement dysregulation (hereditary or acquired), so-called “atypical HUS”

Clinical: **triad** = thrombocytopenia + MAHA + renal failure; (bloody diarrhea if Shiga)

• **Drug-induced TMA** (_Blood_ 2017;129:2857)

Immune-mediated (Ab reacts with plts & endothelial cells): eg, quinine, gemcitabine?

Direct toxicity mediated: eg, gemcitabine, mitomycin, tacrolimus, CsA, bevacizumab

Clinically similar to TTP

• Dx: unexplained **thrombocytopenia** (typically <20k) + **MAHA** → _sufficient for dx_ ⊕ **schistocytes** (>2–3/hpf), ⊖ Coombs, normal PT/PTT & fibrinogen ↑↑ LDH (tissue ischemia + hemolysis), ↑ indirect bili., ↓↓ haptoglobin, ↑ Cr (esp. in HUS)

Biopsy: arterioles filled with platelet hyaline thrombi

Ddx: DIC, vasculitis, malignant hypertension, preeclampsia/HELLP syndrome

• Rx: **urgent plasma exchange** ± glucocorticoids if TTP; FFP if delay to plasma exchange? rituximab or caplacizumab (anti-vWF Ab) (_NEJM_ 2019;380:335) for TTP eculizumab for atypical HUS (_J Nephrol_ 2017;30:127) _plt transfusions contraindicated_ → ↑ microvascular thromb (_NEJM_ 2006;354:1927)

Disseminated intravascular coagulation (DIC): see “Coagulopathies”

DISORDERS OF PLATELET FUNCTION

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Mechanisms and 原因 of Platelet Function Abnormalities</b></p></td></tr><tr><td><p><b>Function</b></p></td><td><p><b>Inherited</b></p></td><td><p><b>Acquired</b></p></td></tr><tr><td><p><b>Adhesion</b></p></td><td><p>Bernard-Soulier; vWD</p></td><td><p>Uremia; acquired vWD</p></td></tr><tr><td><p><b>Aggregation</b></p></td><td><p>Afibrinogenemia</p><p>Glanzmann’s thrombasthenia</p></td><td><p>Ticlopidine, clopidogrel, GP IIb/IIIa</p><p>Dysproteinemias (myeloma)</p></td></tr><tr><td><p><b>Granule</b></p><p><b>release</b></p></td><td><p>Chediak-Higashi syndrome</p><p>Hermansky-Pudlak syndrome</p></td><td><p>Drugs (ASA, NSAIDs); liver disease; MPN; cardiopulmonary bypass</p></td></tr></tbody></table>

Tests of platelet function

• Platelet aggregation tests: measure aggregation in response to agonists (eg, ADP)

von Willebrand’s disease (vWD) (_NEJM_ 2016;375:2067)

• von Willebrand’s factor (vWF) function = platelet glue & plasma carrier of factor VIII

• vWD most common inherited (usually auto dom) bleeding disorder; ~85% (type 1) have partial quantitative defic of vWF, ~15% (type 2) have qualitative defic in vWF

• Acquired vWD: a/w many disorders (malig, MPN with ↑ plt count; autoimmune; hypo-thyroidism; drugs) and caused by different mechanisms (anti-vWF Abs, ↑ clearance, ↓ synthesis); Heyde’s syndrome = vWF destruction by severe AS, a/w GI AVMs/bleed

• Diagnosis: ↓ **vWF:Ag**, ↓ **vWF activity** (measured by ristocetin cofactor assay), ↓ **factor VIII**, ± ↑ PTT, ± ↓ platelets; confirm with **vWF multimer analysis**

• 臨床condition, factor VIII levels and ristocetin cofactor assay useful to guide Rx decision

• Rx: **desmopressin** (dDAVP, IV/IN) → ↑ endothelial cell release of vWF; efficacy depends on type (avoid in type 2), ∴ ✔ response before use with subseq. bleeding or procedures; **vWF replacement:** cryoprecipitate, factor VIII concentrates rich in vWF, recomb. vWF

Uremic bleeding

• Uremia → platelet dysfunction including ↓ aggregation, impaired adhesiveness

• 治療: **dDAVP**, cryoprecipitate, correct anemia (improves plt aggregation and

adhesion by increasing plt interactions with endothelium), consider holding anti-plt agents
